Analyzing G1 Therapeutics (GTHX) and Kindred Biosciences (KIN)
G1 Therapeutics (NASDAQ: GTHX) and Kindred Biosciences (NASDAQ:KIN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ownership.
Valuation and Earnings
This table compares G1 Therapeutics and Kindred Biosciences’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Kindred Biosciences||N/A||N/A||-$22.49 million||($1.17)||-7.22|
Insider and Institutional Ownership
43.3% of G1 Therapeutics shares are held by institutional investors. Comparatively, 66.8% of Kindred Biosciences shares are held by institutional investors. 19.1% of Kindred Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares G1 Therapeutics and Kindred Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent recommendations for G1 Therapeutics and Kindred Biosciences, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
G1 Therapeutics presently has a consensus target price of $31.40, suggesting a potential upside of 36.70%. Kindred Biosciences has a consensus target price of $9.90, suggesting a potential upside of 17.16%. Given G1 Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe G1 Therapeutics is more favorable than Kindred Biosciences.
G1 Therapeutics beats Kindred Biosciences on 5 of the 7 factors compared between the two stocks.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.
Kindred Biosciences Company Profile
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company’s lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company’s other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.